Vlaar, A. P. J., Lim, E. H. T., deBruin, S., Rückinger, S., Pilz, K., Brouwer, M. C., . . . deBeek, D. v. (2022). The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19. Clinical and Translational Science, 15(4), 854. https://doi.org/10.1111/cts.13213
Chicago-referens (17:e uppl.)Vlaar, Alexander P. J., et al. "The Anti‐C5a Antibody Vilobelimab Efficiently Inhibits C5a in Patients with Severe COVID‐19." Clinical and Translational Science 15, no. 4 (2022): 854. https://doi.org/10.1111/cts.13213.
MLA-referens (9:e uppl.)Vlaar, Alexander P. J., et al. "The Anti‐C5a Antibody Vilobelimab Efficiently Inhibits C5a in Patients with Severe COVID‐19." Clinical and Translational Science, vol. 15, no. 4, 2022, p. 854, https://doi.org/10.1111/cts.13213.
